Based: Santa Rosa, California
Investors: Pinnacle Ventures, New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners
Scoop: Boston Scientific made a serious financial commitment to Trivascular when it acquired the smaller drugmaker in 2005, ramping the Trivascular's workforce up to 400 and building a huge new facility for the drugmaker. But TriVascular found itself back in the wild after BS sunk billions into the 2006 acquisition of Guidant. The company was one of many fat-cutting moves BS made after the major acquisition. At that time TriVascular was developing a system to treat abdominal aortic aneurysm, a condition in which the large blood vessel that supplies blood to the abdomen, pelvis, and legs becomes abnormally large or balloons outward.
Fast forward four years and the company is getting ready to launch Ovation Abdominal Stent Graft System in Europe for AAA. The devicemaker was able to gin $60 million to support clinical research of the system and to support late-stage studies of Ovation in the U.S. TriVascular is also testing the Ovation Thoracic Stent Graft System.